PDCD1 and cancer: The therapeutic efficacy of the combination of PD-1 inhibitors plus apatinib in patients with advanced cancer, including esophageal squamous cell carcinoma, gestational trophoblastic neoplasia, biliary tract cancer, and hepatocellular carcinoma, among other cancers, has been reported by previous studies (19–22).